Maze Therapeutics Stock
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company using human genetics to develop small-molecule precision medicines for patients with renal, cardiovascular, and metabolic diseases, including obesity. The company is advancing two programs, MZE829 and MZE782, offering novel precision medicine approaches for chronic kidney disease (CKD).
Founded: 2017
For more Maze Therapeutics stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Management Team
| Jason Coloma Chief Executive Officer |
| Harold Bernstein President, Research and Development and Chief Medical Officer |
| Atul Dandekar Chief Strategy & Business Officer |
